Sadly, colon cancer is a very common cause of cancer-associated death in the United States. However, things may be looking up as data from ongoing trials is uncovered. Explore metastatic colorectal cancer (mCRC) further with Dr. Charles Turck as he speaks with Dr. Richard Kim, Service Chief of Medical Gastrointestinal Oncology at Moffitt Cancer Center in Tampa, Florida, and Dr. Benjamin Weinberg, Associate Professor of Medicine and Attending Physician specializing in Gastrointestinal Medical Oncology and Sarcoma at MedStar Health in Washington, DC.

Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor of Medicine at Harvard Medical School and the Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital.

Since there are limited treatment options available for patients with refractory metastatic colorectal cancer (mCRC), the purpose of this global phase 3 cohort, called FRESCO-2, was to analyze the adverse events of a treatment. Tune into this segment to learn more about this study.

A poster presented at the 2022 American Association for Cancer Research Special Conference on Precision Prevention, Early Detection, and Interception of Cancer found that a four-biomarker class multi-cancer early detection (MCED) test configuration had higher overall sensitivity and specificity compared to a three-biomarker test configuration. These results imply that more early-stage cancers could be detected. Dive further into the data and results with Dr. Charles Turck and Dr. Frank Diehl, Senior Vice President of Multi-Cancer Early Detection at Exact Sciences Corporation and co-author of the poster.

This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.

A recent survey conducted by physicians at Penn Medicine found that one-third of female oncologists reported experiencing infertility. Join Dr. Emily Macduffie, Radiation Oncology Resident Physician at Penn Medicine, as she speaks about potential solutions related to infertility for women in medicine based on her 2023 ASCO presentation.

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.

Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.